Virpax Pharmaceuticals (VRPX) 10-K2023 FY Annual report

Filed: 26 Mar 24, 8:15am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: Actelion, agonist, alleviate, analgesia, ancillary, AnQlarTM, Aravive, argued, arguing, Arizona, await, bar, Barbara, battlefield, Becton, big, Biomedical, biotech, biphasic, Braeburn, bridging, burden, Burke, captioned, CareFusion, Carey, CB, cent, clawback, COA, COBRA, constructive, contend, contoured, copy, creative, CSF, custodian, cyber, de, delisted, delisting, departure, Destum, Dickinson, differentiation, disagreement, Dismissal, dismissing, dissolved, dog, DS, easy, Electroshock, encryption, endocannabinoid, endpoint, enjoining, enzymatic, erroneously, ETSP, excitability, exemplary, fast, fault, Fish, frame, fringe, gas, gastrointestinal, GMP, Gray, Howard, inaccuracy, incident, incision, Indemnity, inert, Insider, insolvency, instruction, involuntary, IP, irreparable, JD, Jude, judgement, KPMG, lA, landscape, leveraging, LGS, Liaison, liver, loyalty, memorandum, Miami, Miller, MIT, MLV, Neave, Neurological, neuronal, Neuroscience, NIST, nonprescription, Northwestern, Novvae, nullified, NY, opposition, Oregon, Otsuka, pathophysiology, peripheral, Plaintiff, planar, Pricewaterhouse, privileged, pro, proactive, proffered, question, Ranchi, rat, rata, reasserting, rebutting, reclassified, reclassifying, regain, regained, reorganization, reply, resurgence, roughly, Ruskin, safeguarded, scanning, Screening, sealed, secondary, Shah, Sheila, Silence, situation, skilled, SOC, software, Southern, spanned, spun, spur, Stipulation, Stroke, subdivided, Sun, suspicion, SVP, symbol, terminology, text, theory, TN, unextended, unspecified, vacation, validly, Vinay, warranty, White, Whitehead, winding, Zoology

Removed: abdominoplasty, accounted, aesthetically, annum, appealing, array, AuRico, BDSI, belief, BMY, bronchial, calling, cholesterol, Combating, commissioner, consult, contractor, converted, coordinating, curved, CVS, deducting, deduction, defer, deferring, Donald, donor, drafting, EKR, emergency, Endo, exploration, facing, Fargo, fill, forged, forgiven, founded, founding, Gammon, GlaxoSmithKline, gold, headcount, hydrogel, illiquid, infectivity, infiltration, inhibition, invest, investor, Jacob, JNJ, launched, layer, lecithin, lender, lessen, Lipogel, loan, localized, manager, mask, materialize, maturity, merger, Mission, ml, offered, officially, ONDCP, outline, Oxley, patch, payroll, Pharmacal, point, PPP, predicted, presence, promissory, prospectively, protective, Purdue, reconstituted, refund, reinforcement, rent, repaid, repayment, replacement, replication, RRD, SBA, spread, tape, taxation, Thornton, Treasury, trillion, Trump, unclear, underwriting, urge, vital, wrote

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

VRPX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the Registration Statement of Virpax Pharmaceuticals, Inc. on Form S-3 (No. 333-267790) and Form S-8 (Nos. 333-255481, 333-264767 and 333-268520) of our report dated March 25, 2024, on our audits of the financial statements as of December 31, 2023 and 2022 and for each of the years then ended, which report is included in this Annual Report on Form 10-K to be filed on or about March 25, 2024. Our report includes an explanatory paragraph about the existence of substantial doubt concerning the Company’s ability to continue as a going concern.

/s/ EisnerAmper LLP

EISNERAMPER LLP

Philadelphia, Pennsylvania

March 25, 2024